This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ott, K. Articles by Weber, W. A. Search for Related Content PubMed PubMed Citation Articles by Ott, K. Articles by Weber, W. A. Social Bookmarking                            What's this?

Prediction of Response to Preoperative Chemotherapy in Gastric Carcinoma by Metabolic Imaging: Results of a Prospective Trial

Katja Ott, Ulrich Fink, Karen Becker, Alexander Stahl, Hans-Joachim Dittler, Raymonde Busch, Hubert Stein, Florian Lordick, Thomas Link, Markus Schwaiger, Jörg-Rüdiger Siewert, Wolfgang A. Weber

From the Departments of Surgery, Nuclear Medicine, Pathology, Radiology, and Medical Statistics, Technische Universität München, Munich, Germany.

Address reprint requests to Katja Ott, MD, Klinikum Rechts der Isar, Ismaningerstrasse 22, 81675 Munich, Germany; e-mail: katja.ott{at}lrz.tum.de.

Purpose: We prospectively evaluated the predictive value of therapy-induced reduction of tumor glucose use for subsequent response and patient survival in patients with gastric cancer treated by preoperative chemotherapy.

Patients and Methods: Forty-four consecutive patients with locally advanced gastric carcinomas were studied by positron emission tomography with the glucose analog fluorine-18 fluorodeoxyglucose (FDG-PET) at baseline and 14 days after initiation of cisplatin-based polychemotherapy. On the basis of a previous study, a reduction of tumor FDG uptake by more than 35% was used as a criterion for a metabolic response. The metabolic response in FDG-PET was correlated with histopathologic response after completion of therapy (< 10% viable tumor cells in the resected specimen) and patient survival.

Results: Thirty-five (80%) of the 44 tumors were visualized with sufficient contrast for quantitative analysis (two of 19 intestinal and seven of 25 nonintestinal tumors showed only low FDG uptake). In the 35 assessable patients, PET imaging after 14 days of therapy correctly predicted histopathologic response after 3 months of therapy in 10 (77%) of 13 responders and 19 (86%) of 22 nonresponders. Median overall survival for patients with a metabolic response has not been reached (2-year survival rate, 90%); for patients without a metabolic response, median survival was only 18.9 months (2-year survival rate, 25%; P = .002)

Conclusion: This study prospectively demonstrates that in patients with gastric cancer, response to preoperative chemotherapy can be predicted by FDG-PET early during the course of therapy. By avoiding the morbidity and costs of ineffective therapy, FDG-PET imaging may markedly facilitate the use of preoperative chemotherapy.

Presented in part at the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, 2002.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors J. Nucl. Med., May 1, 2009; 50(Suppl_1): 122S - 150S. [Abstract] [Full Text] [PDF]

				M. R. Benz, J. Czernin, M. S. Allen-Auerbach, W. D. Tap, S. M. Dry, D. Elashoff, K. Chow, V. Evilevitch, J. J. Eckardt, M. E. Phelps, et al. FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after the Initial Cycle of Neoadjuvant Chemotherapy in High-Grade Soft-Tissue Sarcomas Clin. Cancer Res., April 15, 2009; 15(8): 2856 - 2863. [Abstract] [Full Text] [PDF]

				M. Allen-Auerbach and W. A. Weber Measuring Response with FDG-PET: Methodological Aspects Oncologist, April 1, 2009; 14(4): 369 - 377. [Abstract] [Full Text] [PDF]

				J. Schwarz-Dose, M. Untch, R. Tiling, S. Sassen, S. Mahner, S. Kahlert, N. Harbeck, A. Lebeau, W. Brenner, M. Schwaiger, et al. Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [18F]Fluorodeoxyglucose J. Clin. Oncol., February 1, 2009; 27(4): 535 - 541. [Abstract] [Full Text] [PDF]

				K R Fareed, P Kaye, I N Soomro, M Ilyas, S Martin, S L Parsons, and S Madhusudan Biomarkers of response to therapy in oesophago-gastric cancer Gut, January 1, 2009; 58(1): 127 - 143. [Abstract] [Full Text] [PDF]

				C. Nahmias and L. M. Wahl Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors J. Nucl. Med., November 1, 2008; 49(11): 1804 - 1808. [Abstract] [Full Text] [PDF]

				M. R. Benz, V. Evilevitch, M. S. Allen-Auerbach, F. C. Eilber, M. E. Phelps, J. Czernin, and W. A. Weber Treatment Monitoring by 18F-FDG PET/CT in Patients with Sarcomas: Interobserver Variability of Quantitative Parameters in Treatment-Induced Changes in Histopathologically Responding and Nonresponding Tumors J. Nucl. Med., July 1, 2008; 49(7): 1038 - 1046. [Abstract] [Full Text] [PDF]

				C. Plathow and W. A. Weber Tumor Cell Metabolism Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S. [Abstract] [Full Text] [PDF]

				U. Tateishi, C. Gamez, S. Dawood, H. W. D. Yeung, M. Cristofanilli, and H. A. Macapinlac Bone Metastases in Patients with Metastatic Breast Cancer: Morphologic and Metabolic Monitoring of Response to Systemic Therapy with Integrated PET/CT Radiology, April 1, 2008; 247(1): 189 - 196. [Abstract] [Full Text] [PDF]

				K. Ott, K. Herrmann, F. Lordick, H. Wieder, W. A. Weber, K. Becker, A. K. Buck, M. Dobritz, U. Fink, K. Ulm, et al. Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective Study Clin. Cancer Res., April 1, 2008; 14(7): 2012 - 2018. [Abstract] [Full Text] [PDF]

				J. A. Ajani Can We Understand the Clinical Biology of Gastric Cancer and Exploit it? May be, but It is a Challenge! Ann. Surg. Oncol., December 1, 2007; 14(12): 3290 - 3292. [Full Text] [PDF]

				K. Herrmann, K. Ott, A. K. Buck, F. Lordick, D. Wilhelm, M. Souvatzoglou, K. Becker, T. Schuster, H.-J. Wester, J. R. Siewert, et al. Imaging Gastric Cancer with PET and the Radiotracers 18F-FLT and 18F-FDG: A Comparative Analysis J. Nucl. Med., December 1, 2007; 48(12): 1945 - 1950. [Abstract] [Full Text] [PDF]

				J. K. Schwarz, B. A. Siegel, F. Dehdashti, and P. W. Grigsby Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma JAMA, November 21, 2007; 298(19): 2289 - 2295. [Abstract] [Full Text] [PDF]

				R. Napieralski, K. Ott, M. Kremer, K. Becker, A.-L. Boulesteix, F. Lordick, J. R. Siewert, H. Hofler, and G. Keller Methylation of Tumor-Related Genes in Neoadjuvant-Treated Gastric Cancer: Relation to Therapy Response and Clinicopathologic and Molecular Features Clin. Cancer Res., September 1, 2007; 13(17): 5095 - 5102. [Abstract] [Full Text] [PDF]

				D. P. Kelsen, K. A. Winter, L. L. Gunderson, J. Mortimer, N. C. Estes, D. G. Haller, J. A. Ajani, W. Kocha, B. D. Minsky, J. A. Roth, et al. Long-Term Results of RTOG Trial 8911 (USA Intergroup 113): A Random Assignment Trial Comparison of Chemotherapy Followed by Surgery Compared With Surgery Alone for Esophageal Cancer J. Clin. Oncol., August 20, 2007; 25(24): 3719 - 3725. [Abstract] [Full Text] [PDF]

				C. Nahmias, W. T. Hanna, L. M. Wahl, M. J. Long, K. F. Hubner, and D. W. Townsend Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients with 18F-FDG PET/CT J. Nucl. Med., May 1, 2007; 48(5): 744 - 751. [Abstract] [Full Text] [PDF]

				K. Ott, W. A. Weber, F. Lordick, K. Becker, R. Busch, K. Herrmann, H. Wieder, U. Fink, M. Schwaiger, and J.-R. Siewert Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction J. Clin. Oncol., October 10, 2006; 24(29): 4692 - 4698. [Abstract] [Full Text] [PDF]

				K.-H. Lee, S.-H. Lee, D.-W. Kim, W. J. Kang, J.-K. Chung, S.-A. Im, T.-Y. Kim, Y. W. Kim, Y.-J. Bang, and D. S. Heo High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy. Clin. Cancer Res., July 15, 2006; 12(14): 4232 - 4236. [Abstract] [Full Text] [PDF]

				W. A. Weber Positron Emission Tomography As an Imaging Biomarker J. Clin. Oncol., July 10, 2006; 24(20): 3282 - 3292. [Abstract] [Full Text] [PDF]

				A. J. Beer, H. A. Wieder, F. Lordick, K. Ott, M. Fischer, K. Becker, J. Stollfuss, and E. J. Rummeny Adenocarcinomas of Esophagogastric Junction: Multi-Detector Row CT to Evaluate Early Response to Neoadjuvant Chemotherapy Radiology, May 1, 2006; 239(2): 472 - 480. [Abstract] [Full Text] [PDF]

				M. E. Juweid and B. D. Cheson Positron-Emission Tomography and Assessment of Cancer Therapy N. Engl. J. Med., February 2, 2006; 354(5): 496 - 507. [Full Text] [PDF]

				O. Mawlawi, J. J. Erasmus, R. F. Munden, T. Pan, A. E. Knight, H. A. Macapinlac, D. A. Podoloff, and M. Chasen Quantifying the Effect of IV Contrast Media on Integrated PET/CT: Clinical Evaluation Am. J. Roentgenol., February 1, 2006; 186(2): 308 - 319. [Abstract] [Full Text] [PDF]

				J. S. Lim, M. J. Yun, M.-J. Kim, W. J. Hyung, M.-S. Park, J.-Y. Choi, T.-S. Kim, J. D. Lee, S. H. Noh, and K. W. Kim CT and PET in Stomach Cancer: Preoperative Staging and Monitoring of Response to Therapy RadioGraphics, January 1, 2006; 26(1): 143 - 156. [Abstract] [Full Text] [PDF]

				D. S. Hawkins, S. M. Schuetze, J. E. Butrynski, J. G. Rajendran, C. B. Vernon, E. U. Conrad III, and J. F. Eary [18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Outcome for Ewing Sarcoma Family of Tumors J. Clin. Oncol., December 1, 2005; 23(34): 8828 - 8834. [Abstract] [Full Text] [PDF]

				H. A. Wieder, A. J. Beer, F. Lordick, K. Ott, M. Fischer, E. J. Rummeny, S. Ziegler, J. R. Siewer, M. Schwaiger, and W. A. Weber Comparison of Changes in Tumor Metabolic Activity and Tumor Size During Chemotherapy of Adenocarcinomas of the Esophagogastric Junction J. Nucl. Med., December 1, 2005; 46(12): 2029 - 2034. [Abstract] [Full Text] [PDF]

				W A Weber PET for response assessment in oncology: radiotherapy and chemotherapy Br. J. Radiol., November 1, 2005; Supplement_28(1): 42 - 49. [Abstract] [Full Text] [PDF]

				N. Avril, S. Sassen, B. Schmalfeldt, J. Naehrig, S. Rutke, W. A. Weber, M. Werner, H. Graeff, M. Schwaiger, and W. Kuhn Prediction of Response to Neoadjuvant Chemotherapy by Sequential F-18-Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced-Stage Ovarian Cancer J. Clin. Oncol., October 20, 2005; 23(30): 7445 - 7453. [Abstract] [Full Text] [PDF]

				J. Dose Schwarz, M. Bader, L. Jenicke, G. Hemminger, F. Janicke, and N. Avril Early Prediction of Response to Chemotherapy in Metastatic Breast Cancer Using Sequential 18F-FDG PET J. Nucl. Med., July 1, 2005; 46(7): 1144 - 1150. [Abstract] [Full Text] [PDF]

				W. A. Weber Use of PET for Monitoring Cancer Therapy and for Predicting Outcome J. Nucl. Med., June 1, 2005; 46(6): 983 - 995. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808. [Abstract] [Full Text] [PDF]

				R. Napieralski, K. Ott, M. Kremer, K. Specht, H. Vogelsang, K. Becker, M. Muller, F. Lordick, U. Fink, J. Rudiger Siewert, et al. Combined GADD45A and Thymidine Phosphorylase Expression Levels Predict Response and Survival of Neoadjuvant-Treated Gastric Cancer Patients Clin. Cancer Res., April 15, 2005; 11(8): 3025 - 3031. [Abstract] [Full Text] [PDF]

				S. G. Swisher, M. Maish, J. J. Erasmus, A. M. Correa, J. A. Ajani, R. Bresalier, R. Komaki, H. Macapinlac, R. F. Munden, J. B. Putnam, et al. Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer Ann. Thorac. Surg., October 1, 2004; 78(4): 1152 - 1160. [Abstract] [Full Text] [PDF]

				V. Voelter, C. Schuhmacher, R. Busch, C. Peschel, J. R. Siewert, and F. Lordick Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer Ann. Thorac. Surg., September 1, 2004; 78(3): 1037 - 1041. [Abstract] [Full Text] [PDF]